trial

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

NCTId NCT00506077
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 55 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2008-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
55 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2007-12
Primary completion
2008-10
Eligibility
ALL · 21 Years · 55 Years

Interventions & indications

Drugs
MK0249

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia — primary completion2008-10

Facts & assertions

4 sourced
Enrollment
55
Phase
PHASE2
Primary Completion Date
2008-10
Status
COMPLETED
relationships
The graph out of here
drug
MK0249
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia, Paranoid
indication
Paranoid Schizophrenia
indication